RegulatoryOfficial
MHRA publishes Women's Health Programme for 2026-2030 to strengthen evidence and regulation
🇬🇧 MHRA · Mon 16 Nov 2026
The UK regulator's 32-page corporate report aims to improve the safety and effectiveness of medicines and medical devices used by women, within its wider strategy to 2030.
The Medicines and Healthcare products Regulatory Agency (MHRA) has published its Women's Health Programme 2026-2030, a corporate report setting out how it intends to improve the evidence base and regulation of medicines and medical devices so that health outcomes for women improve. The document was published on 16 November 2026 and runs to 32 pages.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Article written by VigiEye from the official source (MHRA). AI-assisted; check the source before acting.
More Regulatory
All →
Galectin files belapectin Phase 3 protocol with FDA as chairman converts $105.8M debt
🇺🇸 Galectin Therapeutics Inc (GALT) · Mon 16 Nov 2026
Apnimed's sleep apnoea drug AD109 awaits FDA decision with 28 February 2027 goal date
🇺🇸 Apnimed, Inc. (APMD) · Mon 16 Nov 2026
FDA sets 25 March 2027 goal date for Unicycive's resubmitted oxylanthanum carbonate application
🇺🇸 Unicycive Therapeutics, Inc. (UNCY) · Mon 16 Nov 2026
FDA grants orphan drug designation to Noema's basimglurant for trigeminal neuralgia
Noema Pharma AG · Mon 16 Nov 2026
FDA issues complete response letter for Summit's ivonescimab in EGFR-mutant NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Mon 16 Nov 2026
Invivyd Q3 Pemgarda revenue reaches $15.4M as VYD2311 data timing shifts after FDA talks
🇺🇸 Invivyd, Inc. (IVVD) · Mon 16 Nov 2026